Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195175 | 0.78 | ALDH1A1 (0.36) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL13853252 | 0.75 | PDE4A (0.36) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL13853257 | 0.75 | ADK (0.44) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL5264672 | 0.75 | ALDH1A1 (0.36) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL13853282 | 0.75 | ALDH1A1 (0.39) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL5262734 | 0.74 | ALDH1A1 (0.43) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL15267989 | 0.74 | MAT2A (0.42) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL13853272 | 0.73 | PDE4B (0.39) | ALDH1A1KDM4EKMT2ATRPV1 | |
| SCHEMBL13853267 | 0.73 | ALDH1A1 (0.36) | ALDH1A1KDM4EKMT2AGAAMAPT | |
| SCHEMBL13853256 | 0.72 | ALDH1A1 (0.35) | ALDH1A1KDM4EKMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PEAKDALE MOLECULAR LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PEAKDALE MOLECULAR LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PNPO, CYP4B1, PDXK | ALDH1A1 290/4885KDM4E 376/4885KMT2A 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.